arrow
G

Giulia Benevolo

città della salute e della scienza
H指数:40
被引数:7,020

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term deepening of JAK2V617F molecular response with low-dose ropeginterferon in low-risk polycythaemia vera

低剂量罗肽干扰素在低风险真性红细胞增多症中实现<i>JAK2V617F</i>分子反应的长期深化

2026-10-260
PRE
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib

鲁索利替尼治疗患者的真性红细胞增多症长期结局动态预测模型

2026-06-150
OAAI
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study

美洛替尼在鲁索利替尼治疗失败后的临床获益及疗效预测因素:一项合作性真实世界研究

Cancer
IF5.1
2026-05-120
OAAI
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study

定量MYD88 L265P和流式细胞术水平用于IgM异常免疫球蛋白病的预后判断:SAL-TO研究

2026-03-250
OAAI
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström Macroglobulinaemia? A real-life multicentre Italian study.

伊布替尼或非BTK抑制剂疗法在复发华氏巨球蛋白血症中的应用?一项意大利多中心真实世界研究。

2026-02-160
OAAI
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

硼替佐米-美法仑-泼尼松与来那度胺-地塞米松在老年多发性骨髓瘤患者中的应用比较:Real MM IV期临床试验

2026-01-010
OA
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial

卡非佐米–来那度胺–地塞米松与来那度胺–地塞米松治疗不符合自体干细胞移植条件的初诊骨髓瘤患者的比较(EMN20):一项随机、开放标签、多中心、III期临床试验

2025-08-040
PRE
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI
First-line treatment of Waldenstrom's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
2024-11-190
OAAI
Long Term Follow-up of Rituximab for Anti-Myelin-Associated Glycoprotein Demyelinating Polyneuropathy in IgM Gammopathies: Clinical, Hematological and Neurophysiological Correlations

利妥昔单抗治疗IgM异常蛋白血症相关抗髓鞘相关糖蛋白脱髓鞘多发性神经病的长期随访:临床、血液学和神经生理学相关性

BLOOD
IF23.1
2024-11-050
PRE
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

细胞因子调节与接受Nuvisertib(TP-3654)治疗骨髓纤维化患者的症状改善显著相关,Nuvisertib是一种在研的选择性PIM1激酶抑制剂。

BLOOD
IF23.1
2024-11-050
PRE
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
CANCER
IF5.1
2024-07-301
OAAI
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
CANCER
IF5.1
2023-12-284
OAAI
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2023-12-077
PRE
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023-05-030
OAAI
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
CANCER
IF5.1
2023-03-1821
OAAI